Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 0.7% – Here’s What Happened

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares dropped 0.7% during trading on Monday . The stock traded as low as $1.35 and last traded at $1.40. Approximately 114,646 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 245,140 shares. The stock had previously closed at $1.41.

Wall Street Analyst Weigh In

TLSA has been the topic of several analyst reports. Wall Street Zen cut Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings cut shares of Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Tiziana Life Sciences Stock Performance

The firm has a 50-day moving average price of $1.34 and a 200-day moving average price of $1.46.

Tiziana Life Sciences (NASDAQ:TLSA) last announced its quarterly earnings data on Friday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Tiziana Life Sciences

Hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new position in shares of Tiziana Life Sciences in the 1st quarter worth $25,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Tiziana Life Sciences in the 4th quarter worth $25,000. Bison Wealth LLC acquired a new position in shares of Tiziana Life Sciences in the 4th quarter worth $30,000. HRT Financial LP acquired a new position in shares of Tiziana Life Sciences in the 4th quarter worth $36,000. Finally, Marshall Wace LLP acquired a new position in shares of Tiziana Life Sciences in the 2nd quarter worth $39,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.